

Pathway Transformation Fund 2020/21

Guidance for Lipid Management RUP

Overview

The Pathway Transformation Fund (PTF) is available to help providers to overcome implementation barriers to the deployment and adoption of Rapid Uptake Products (RUPs).

This guidance note provides is supplementary to the main application guidance, and provides additional information to help you make a successful PTF application for the Lipid Management RUP.

It sets out some suggested activities and how they could be delivered, in order to address the barriers to implementation that have been identified by the Product Working Group (PWG). For further advice and guidance please consult with your AHSN RUP lead.

RUP priority actions

PTF is available for providers to deploy innovative ideas and solutions to overcome barriers to spread and adoption of RUPs in their locality. The following are priorities for the Lipid Management RUP and applications addressing these actions will be welcomed.

Priority	Description
Improve the spread, and adoption of the AAC produced, NICE-endorsed lipid management pathway.	The AAC have produced a NICE-endorsed lipid management clinical pathway. Improving uptake on this pathway will help improve patient outcomes and reduce hospitalisations.
Educate patients and the public on lipid lowering medicines and their importance.	There is a lot of misinformation on the benefits of taking statins. Educating on the benefits of taking statins, will improve their uptake and patient adherence.
Adopting and deploying search strategy methodologies to identify patients at high risk or eligible for PCSK9i.	Identifying patients at risk will help to know where resources should be targeted.
Pathway redesign to improve the interface between primary care and secondary care in line with innovative models of care delivery for lipid management.	The NICE-endorsed lipid management pathway focuses on both primary and secondary care medicines. Redesigning the care pathway to better manage will improve patient outcomes.
Addressing specific population inequalities in prevalence, access, clinical outcome or experience relating to lipid management.	Cardiovascular disease causes a quarter of all deaths in the UK and is the largest cause of premature mortality in deprived areas. Addressing inequalities will help improve patient outcomes.



Models of delivery and Evaluation of Impact

We welcome innovative models for the delivery of proposed projects to address barriers, including new ways of partnership working. The following are some suggestions for models of delivery that have been identified by the Product Working Group:

- Address poor adherence to medicines by working with patients and their families to co-produce solutions e.g. shared decision making or care plans
- Improving the capacity of general practice for annual reviews, e.g. by utilising community pharmacy as a hub for point of care testing
- Working across a PCN e.g. centralised lipid clinics with specialists
- Designing solutions which work across an ICS for whole populations
- Working with charities and social care to enhance current care offering

All models should include information on how patients and their families have, or will be, involved in co-design and delivery and an assessment of diversity and equality impact. Applications must also include details of how you will measure and evaluate your project.

Tips for a successful application

- Ensure that you have liaised with your local AHSN Project Manager for your RUP
- Understand the priorities for implementation of the RUP that have been identified by the Product Working Group

Please refer to the main PTF application guidance for more information.

Applications should be submitted via your AHSN Project Manager to: the AAC RUP Delivery Team c/o England.ptf@nhs.net

